A prospective multicenter randomized controlled clinical study of interferon reversal of HPV infection after coning of high-grade squamous intraepithelial lesion of the cervix

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600117050

Enrollment

Unknown

Registered

2026-01-19

Start date

2021-07-12

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical high-grade squamous intraepithelial lesion

Interventions

Medication group:Treatment with interferon

Control group:no medication

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) 18-65 years old, having sexual life; (2) High-risk HPV infection and high-grade squamous intraepithelial lesion (HSIL) confirmed by pathology after conization; (3) Negative pregnancy test; (4) Not use other cervical drugs in the past 3 months; (5) Good compliance and signed informed consent

Exclusion criteria

Exclusion criteria: (1) Less than 18 or more than 65 years old; (2) In pregnancy or lactation; (3) Allergic to study drug; (4) Patients with surgical contraindications (such as severe heart, lung, liver and kidney diseases) or cervical cancer; (5) Patients with immunosuppressive agents or with immune system diseases or malignant tumors; (6) Patients with acute genital tract inflammation; (7) Not sign informed consent.

Design outcomes

Primary

Measure	Time frame
The positive rate of human papillomavirus infection;	—

Secondary

Measure	Time frame
Recurrence rate of cervical squamous intraepithelial lesion;	—

Countries

China

Contacts

Public ContactXuejun Chen

Second Affiliated Hospital, Zhejiang University School of Medicine

2303011@zju.edu.cn+86 137 5711 9632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026